Indian journal of cancer最新文献

{"title":"High-dose rate intraluminal brachytherapy in ano-rectum for haemostasis in a case of metastatic infiltrating cancer prostate.","authors":"Ashok Kumar, Manoj K Semwal, Bhanu Prakash, Prabhjeet Bhatla, Nilima Mishra","doi":"10.4103/ijc.ijc_280_22","DOIUrl":"https://doi.org/10.4103/ijc.ijc_280_22","url":null,"abstract":"<p><strong>Abstract: </strong>Management of rectal bleeding due to various underlying malignant pathologies is a difficult situation, especially in the setting of metastatic disease. Palliative radiation is generally offered to such patients to achieve hemostasis. We report a patient diagnosed with metastatic prostate carcinoma which was infiltrating the rectal mucosa. Fifty-four year old patient, with a case of metastatic prostate carcinoma presented with rectal bleeding. On evaluation, he had a friable growth from the anal verge to 10 cm with severe bleeding. We gave intraluminal high-dose rate brachytherapy using an endoluminal vaginal/rectal cylinder applicator. A dose of 6 Gy, weekly for three weeks was delivered. High-dose-rate brachytherapy was immediately well tolerated. The bleeding stopped completely by day 4 and by day 7 patient was passing yellow stools. Intraluminal high-dose-rate brachytherapy has been proven as an effective palliative treatment in achieving hemostasis from rectal bleeding.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"565-568"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult-type epithelial neoplasms in children and adolescents-A retrospective analysis on a subgroup of very rare tumors.","authors":"Gazel Sainulabdin, V P Krishnan, Smitha Bhaskaran, Yamini Krishnan","doi":"10.4103/ijc.ijc_96_25","DOIUrl":"https://doi.org/10.4103/ijc.ijc_96_25","url":null,"abstract":"<p><strong>Background: </strong>Epithelial malignancies, which constitute the majority of adult cancers, are relatively rare in the pediatric population, accounting for only 2% of all childhood tumors. In contrast to common childhood cancers-which typically arise from embryonal or mesenchymal tissues-epithelial malignancies originate from the epithelial lining of glands and include carcinomas of the lung, breast, colon, and genitourinary tract. Understanding the occurrence, behavior, and treatment outcomes of adult-type epithelial malignancies in children is essential for developing age-appropriate management strategies and improving long-term survival. This emerging subset of pediatric cancers warrants further investigation and collaborative efforts to establish optimal diagnostic criteria, staging systems, and therapeutic approaches tailored to younger patients. We undertook a 5-year retrospective analysis of children diagnosed with adult-type epithelial malignancies at our center.</p><p><strong>Methods: </strong>Study Design: This is a retrospective data analysis conducted at MVR Cancer Centre and Research Institute (MVRCCRI), focusing on pediatric patients below 18 years of age who presented between the years January 2019 and December 2024. Inclusion criteria: All children under 18 years of age who presented to MVRCCRI provided they had an adult-type neoplasm of epithelial origin were included in this study. Statistical analysis was performed. The mean, intervals and percentages in each group were calculated. Institutional ethical committee approval was obtained for this retrospective review.</p><p><strong>Results: </strong>A total of 69 children who were younger than 18 years were included in the study. There were 18 males and 51 females in the study giving a male to female ratio of 1:2.8. Three children had a family history of malignancy: one had a history of consanguinity was diagnosed with CMMRD on genetic evaluation, and the other had a mother with breast cancer and a pathological variant in the ATM gene. The third child with adrenocortical carcinoma had a pathological variant in TP53 diagnosed in mother. The children were analyzed based on the primary diagnosis. The largest group of epithelial malignancies in our cohort was thyroid malignancy, and the second largest group was carcinoma of the salivary glands. Children who presented with early stages of disease fared well in all the groups.</p><p><strong>Conclusion: </strong>Adult-type epithelial neoplasms in children and adolescents are distinct entities, characterized by unique biological behaviors and genetic signatures. Treatment approaches should integrate principles from adult oncology and collaborative studies are essential to define the epidemiology, for staging and prognostic markers, and also to develop pediatric-specific treatment protocols for these malignancies.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"528-534"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing the enhanced recovery after surgery (ERAS) protocol for oncosurgeries in a tertiary level hospital in South India: Key steps and early outcomes.","authors":"Ashu S Mathai, Jithin M Abraham, Gincy A Lukachan, Nimmy Raju, Neethu Thankam, Litty B George, Sangeetha M Varghese","doi":"10.4103/ijc.ijc_706_24","DOIUrl":"https://doi.org/10.4103/ijc.ijc_706_24","url":null,"abstract":"<p><strong>Background: </strong>The enhanced recovery after surgery (ERAS) pathway is the standard of perioperative care for major surgeries globally. However, integrating it into practice can be challenging, especially given the variety of healthcare systems in low- and middle-income countries. At our hospital, we aimed to establish the ERAS pathway phase-wise for oncosurgeries.</p><p><strong>Methods: </strong>We initiated the ERAS pathway in incremental steps, namely, drafting and team-building, trial run, consolidation, and expansion, with regular auditing and feedback at every stage. Six months after initiation (January to June 2024), we assessed our compliance rates and compared outcomes with historical controls (matched for age, surgical procedure, and ASA classification).</p><p><strong>Results: </strong>In the oncosurgical patients managed under the ERAS protocol, overall compliance was 70.4%, with maximum compliance for preoperative (77.17%) and least for postoperative elements (54.16%). Compared to matched cohorts, ERAS patients had significantly lower rates of postoperative complications (median ± IQR, 1.00 ± 0.00 versus 1.50 ± 1.00, P = 0.035) and duration of ICU (median ± IQR, 0.00 ± 2.00 versus 2.00 ± 3.00, P = 0.017) and hospital stay (median ± IQR, 7.00 ± 2.00 versus 8.00 ± 4.00, P = 0.035).</p><p><strong>Conclusions: </strong>Anesthesiologists can champion and build ERAS care pathways in hospitals by assembling a core team and systematically applying ERAS components during each surgical stage.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"513-520"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolving burden of pediatric solid tumors: A global analysis from 1990 to 2021.","authors":"Gang Xiao, Qidong Ye","doi":"10.4103/ijc.ijc_82_25","DOIUrl":"https://doi.org/10.4103/ijc.ijc_82_25","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the global incidence and mortality trends of seven major solid tumors (brain cancer, hepatoblastoma, kidney cancer, malignant bone tumors [MNBAC], neuroblastoma, retinoblastoma, and soft tissue sarcomas) in individuals aged 0-19 years from 1990 to 2021.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease Study 2021, analyses were stratified by age, region, and sociodemographic index (SDI). Temporal trends were quantified via estimated annual percentage change (EAPC). A linear regression model evaluated the correlation between childhood meningitis mortality and SDI.</p><p><strong>Results: </strong>In 2021, these tumors accounted for 96,913 new cases and 42,869 deaths worldwide. Brain cancer and MNBAC were the most common and fatal. Retinoblastoma showed the largest incidence increase, while neuroblastoma was the only tumor with rising mortality. Major regional disparities were observed, with East Asia having the highest brain cancer burden and sub-Saharan Africa experiencing the greatest retinoblastoma mortality. Incidence peaked in infants for hepatoblastoma, neuroblastoma, and soft tissue sarcomas, and in adolescents for bone tumors. Higher SDI correlated with higher neuroblastoma incidence, while lower-SDI regions had elevated mortality for multiple tumors.</p><p><strong>Conclusion: </strong>Substantial global and regional disparities persist in the burden of pediatric solid tumors. Enhancing early detection in low-SDI regions and implementing targeted strategies for high-burden tumors such as brain cancer and MNBAC are essential to reducing mortality.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"493-512"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of miRNA in diagnosis of Wilms tumor and neuroblastoma.","authors":"Disha Kakkar, Saumyaranjan Mallick, Aijaz Ahmad, Ansh Goswami, Sandeep Agarwala, Aditya K Gupta, Sameer Bakhshi, K Devasenathipathy, Sandeep Mathur, Jagdish Prasad, Deepali Jain, Rachana Seth, Venkateswaran K Iyer","doi":"10.4103/ijc.ijc_1255_22","DOIUrl":"https://doi.org/10.4103/ijc.ijc_1255_22","url":null,"abstract":"<p><strong>Background: </strong>Wilms tumor (WT) and Neuroblastoma (Nb) are the two most common pediatric abdominal tumors that are difficult to differentiate due to anatomical proximity and often need an invasive procedure such as fine needle aspiration or biopsy. Pediatric tumors have differential expression of miRNA that can be used as a non invasive method to differentiate. Based upon the existing published literature, we designed a panel of four miRNAs (miR1180, miR143, miR124, and miR34a) to differentiate WT from Nb.</p><p><strong>Methods: </strong>This was a prospective study conducted over 2 years (2019-2021) at our center. A total of 17 cases, including 10 cases of WT and seven cases of Nb, were included in this study. Ribonucleic acid (RNA) extraction was conducted after confirmation of diagnosis, which was reverse transcribed to complementary deoxyribonucleic acid (cDNA). Real time polymerase chain reaction using cDNA was performed for analyzing expression levels of miR1180, 143, 124, and 34a.</p><p><strong>Results: </strong>The two biomarkers differentially expressed between these patients are miR143 and miR124 3p. miR143 is down regulated in WT (80% of cases), while up regulated in Nb (71.4% of cases), while miR124 3p is up regulated in WT (6/10:60%) and down-regulated in Nb cases.</p><p><strong>Conclusions: </strong>We conclude that miR143 and 124 might prove as useful biomarkers to differentiate between WT and Nb; however, more comprehensive evaluation is required for confirmation of the same.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"521-527"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pleomorphic undifferentiated sarcoma arising in a burn scar: Report of a case and review of literature.","authors":"Ranganath Ratnagiri, Shantveer G Uppin","doi":"10.4103/ijc.ijc_511_22","DOIUrl":"https://doi.org/10.4103/ijc.ijc_511_22","url":null,"abstract":"<p><strong>Abstract: </strong>The skin is the largest organ in the human body, and skin cancers are some of the most common malignancies seen across the world. About 80% of all skin cancers are basal cell carcinomas (BCC), 16% are squamous cell cancers (SCC), and 4% are melanomas. In contrast, the most common cancers that arise in a burn scar are squamous cell cancers. The burned area is at risk of constant and chronic irritation due to activities of daily living because the covering lacks hydration and elasticity, as compared to normal skin. Malignant transformation of these areas is accelerated by the prolonged duration of the ulcer, injury, constant irritation, infection, and poor hygiene. There have been anecdotal reports of sarcomas arising in a burn scar, with a total of 21 cases being reported so far in the literature. We present the clinical and pathological details of a 50-year-old lady with a pleomorphic undifferentiated sarcoma arising from a neglected burn scar, who needed palliative surgery to relieve her pain. This case report focuses attention on an unusual presentation of an aggressive tumor in the background of a neglected burn scar and emphasizes the need for early and appropriate management of all non-fatal burn patients.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"557-559"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial papillary thyroid cancer; A male case with breast and thyroid cancer and his three sisters with thyroid cancer: A case series and review of the literature.","authors":"Sevde N Fırat, Abdullah Durhan","doi":"10.4103/ijc.ijc_520_22","DOIUrl":"https://doi.org/10.4103/ijc.ijc_520_22","url":null,"abstract":"<p><strong>Abstract: </strong>Thyroid cancer is the most widespread endocrine malignancy. Of all the cases of thyroid cancer, approximately 95% arise from follicular cells. Familial non-medullary thyroid cancers constitute 3-9% of all the reported cases of thyroid cancer and are diagnosed by the presence of two or more first-degree relatives with cancer. Most familial cases of non-medullary thyroid cancer are caused by papillary thyroid cancer and its histological variants. Although some genes predisposing to familial papillary thyroid cancer have been identified, their functionality is unclear, and routine examination is not recommended. Some of these cases may be syndromic, but most cases (>95%) are non-syndromic. Various researchers have suggested an association between familial papillary thyroid cancers and earlier age of onset, higher multifocal tumor rate, extrathyroid enlargement, lymph node metastasis, and disease recurrence. Therefore, screening and close follow-up of other family members are essential when familial papillary cancer is diagnosed. This case report presents a familial papillary thyroid cancer series involving an index male patient with a breast cancer history and his three sisters with thyroid papillary cancer.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"552-556"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adrenocortical carcinoma presenting with extensive striae: A case report and literature review.","authors":"Ayse Ozden, Zerrin Orbak, Ebru Sener, Gozde Doymus, Hakan Doneray","doi":"10.4103/ijc.ijc_87_24","DOIUrl":"https://doi.org/10.4103/ijc.ijc_87_24","url":null,"abstract":"<p><strong>Abstract: </strong>Adrenocortical tumors are rare tumors in childhood. Virilization is the most common symptom, but about 5.5% of patients may also present with isolated Cushing's syndrome. A girl 15 years and 8 months of age presented with complaints of striae on her legs, acne for 2 weeks, and amenorrhea for 2 months. On physical examination, extensive striae were observed on her legs and abdomen. On hormonal investigation, her adrenocorticotropic hormone level was <5 pg/ml, cortisol was 35.4 µg/dl. Her hypercortisolism raised suspicion of Cushing's syndrome. Adrenal MRI revealed a right adrenal mass approximately 9 cm in diameter. Pleural metastasis was detected and the patient was diagnosed as having stage 4 adrenocortical carcinoma. Despite treatment, she died 9 months after diagnosis. Our case followed an aggressive clinical course and was unique due to the presence of extensive striae without pronounced virilization or Cushingoid symptoms.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"548-551"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cetuximab in platinum-ineligible patients with locally advanced squamous cell carcinoma of the head and neck: Consensus from India.","authors":"Agarwala Vivek, Aggarwal Shyam, Agrawal Shyam, M V Chandrakanth, Choudhary Vaibhav, S Dattatreya Palanki, Gore Adwaita, Kapoor Akhil, Kumar Prabhash, M Lokeshwar Nilesh, M Vamshi Krishna, K Vaid Ashok, N P Mohapatra, B Parekh Bhavesh, Patel Kaushal, Saha Rajat, Singh Ashish, Singh Randeep, Talreja Vikas, S Udupa Karthik, Gajanan Panchal, Maneesha Khalse, Gurunath Chavan","doi":"10.4103/ijc.ijc_862_24","DOIUrl":"10.4103/ijc.ijc_862_24","url":null,"abstract":"<p><strong>Abstract: </strong>Locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN) are one of the most common cancers globally and in India. Though many treatment options are available for LA-SCHHN, chemotherapy administered concurrently with radiotherapy (CCRT) is the most common treatment modality. Cisplatin-based CCRT is the guideline-recommended standard of care (SoC) in definitive and adjuvant settings. However, cisplatin-based CCRT often fails or cannot be administered due to toxicity. Hence, 60% of LA-SCCHN patients experience locoregional recurrence, and 20% experience distant metastasis. Many of these patients are cisplatin-ineligible/unfit due to absolute or relative contraindications; thus, continued cisplatin-based CCRT is unsuitable for them. Hence, alternative treatment strategies have been suggested for cisplatin-unfit LA-SCCHN patients and include docetaxel, carboplatin, and cetuximab-based regimens. Of these, docetaxel and carboplatin-based regimens have an unfavorable toxicity profile when compared with cetuximab-based regimens. Additionally, cetuximab-based regimens have demonstrated good locoregional control (LRC), improved disease-free survival (DFS), and OS (including 5-year OS) in LA-SCCHN patients. Therefore, Indian and international guidelines recommend cetuximab-based regimens for cisplatin-ineligible/unfit LA-SCCHN patients, Cetuximab is a costly drug for Indian patients. However, with the availability of cetuximab biosimilars, it has become possible to extend the drug's benefits to cisplatin-ineligible/unfit LA-SCCHN patients in India. Hence, this Expert opinion from India was organized, and nine consensus statements were drafted to highlight the various clinical settings where cetuximab-based regimens can benefit cisplatin-ineligible/unfit LA-SCCHN patients. An attempt was also made to understand the burden and causes of cisplatin ineligibility and toxicity in Indian patients.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"480-492"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berberine's role in enhancing lung cancer treatment: Exploring mechanisms, efficacy, and adjuvant potential.","authors":"Manju Bargavi Sakthivel, Prabhavathy Devi Narayanan Doss, Malchi Suresh, Tharani Munusamy, Nalini Devarajan, Naresh Kumar Kodaganti","doi":"10.4103/ijc.ijc_846_24","DOIUrl":"https://doi.org/10.4103/ijc.ijc_846_24","url":null,"abstract":"<p><strong>Abstract: </strong>Berberine (BBR), a bioactive compound from various plants, shows significant therapeutic promise against lung cancer. Research indicates that berberine effectively inhibits cell proliferation in lung cancer cell lines and promotes apoptosis. Its mechanisms of action include inducing apoptosis and inhibiting metastasis-related pathways, showcasing its multifaceted approach to tumor suppression. Berberine also influences important signaling pathways like mitogen-activated protein kinase, phosphoinositide 3-kinase/protein kinase B, and nuclear factor kappa-light-chain-enhancer of activated B cells, thereby boosting its anti-cancer properties. Preclinical animal studies have further demonstrated berberine's effectiveness, especially when combined with conventional chemotherapy, suggesting a synergistic relationship that could enhance treatment efficacy. These promising results have led to ongoing clinical trials exploring berberine's potential as part of lung cancer treatment regimens. However, challenges persist regarding dosage standardization, bioavailability, and the translation of preclinical results into clinical applications. This review highlights the therapeutic mechanisms of berberine, its potential efficacy as a standalone or adjunctive treatment, and the obstacles that must be addressed to leverage its benefits in lung cancer therapy fully. Overcoming these challenges may provide valuable opportunities for improving treatment outcomes, positioning berberine as a key component in future lung cancer therapies. Continued research is essential to better understand its precise mechanisms and enhance its clinical application.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"471-479"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}